合作
Eli Lilly targets vaccines with $3.8B acquisition of three biotech firms
Eli Lilly announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics and Vaccine Company, for a combined value of up to $3.8 billion, expanding its push into infectious-disease vaccines.